Sumitomo Chemical India Ltd
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.[1] [2]
- Market Cap ₹ 26,000 Cr.
- Current Price ₹ 521
- High / Low ₹ 628 / 336
- Stock P/E 53.8
- Book Value ₹ 54.4
- Dividend Yield 0.17 %
- ROCE 19.8 %
- ROE 14.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.5%
Cons
- Stock is trading at 9.58 times its book value
- The company has delivered a poor sales growth of 5.00% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Part of BSE 400 MidSmallCap Index BSE 250 SmallCap Index BSE Commodities Nifty MidSmallcap 400 Nifty Midcap150 Quality 50
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 1,913 | 2,228 | 2,425 | 2,645 | 3,061 | 3,511 | 2,844 | 3,043 | |
| 1,693 | 1,938 | 2,090 | 2,157 | 2,459 | 2,844 | 2,369 | 2,431 | |
| Operating Profit | 220 | 291 | 335 | 488 | 602 | 667 | 475 | 612 |
| OPM % | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% |
| 30 | 1 | -20 | 19 | 27 | 45 | 96 | 111 | |
| Interest | 5 | 4 | 7 | 7 | 8 | 6 | 6 | 5 |
| Depreciation | 24 | 28 | 41 | 47 | 45 | 52 | 62 | 63 |
| Profit before tax | 221 | 260 | 267 | 453 | 576 | 654 | 503 | 655 |
| Tax % | 34% | 36% | 23% | 24% | 26% | 23% | 26% | |
| 145 | 166 | 205 | 345 | 424 | 502 | 370 | 484 | |
| EPS in Rs | 4.10 | 6.92 | 8.49 | 10.06 | 7.40 | 9.69 | ||
| Dividend Payout % | 0% | 38% | 18% | 12% | 12% | 12% | 80% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 2% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 1% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 11% |
| 1 Year: | 33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 20% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | 679 | 774 | 723 | 1,042 | 1,428 | 1,883 | 1,942 | 2,214 |
| 10 | 20 | 36 | 33 | 38 | 34 | 30 | 29 | |
| 694 | 792 | 849 | 1,098 | 1,045 | 953 | 841 | 1,100 | |
| Total Liabilities | 1,658 | 1,860 | 2,106 | 2,672 | 3,010 | 3,369 | 3,313 | 3,843 |
| 267 | 279 | 319 | 309 | 390 | 430 | 563 | 563 | |
| CWIP | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 9 |
| Investments | 0 | 0 | 86 | 290 | 356 | 239 | 346 | 546 |
| 1,383 | 1,572 | 1,690 | 2,058 | 2,228 | 2,629 | 2,381 | 2,726 | |
| Total Assets | 1,658 | 1,860 | 2,106 | 2,672 | 3,010 | 3,369 | 3,313 | 3,843 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| 47 | 78 | 221 | 425 | 222 | 389 | 757 | |
| -40 | -35 | -118 | -283 | -290 | -327 | -420 | |
| 7 | -65 | -61 | -47 | -63 | -73 | -337 | |
| Net Cash Flow | 15 | -23 | 42 | 96 | -131 | -10 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 110 | 128 | 117 | 101 | 98 | 92 |
| Inventory Days | 203 | 193 | 146 | 185 | 198 | 157 | 136 |
| Days Payable | 176 | 136 | 122 | 145 | 109 | 86 | 96 |
| Cash Conversion Cycle | 133 | 166 | 152 | 157 | 189 | 169 | 132 |
| Working Capital Days | 116 | 119 | 112 | 98 | 129 | 138 | 174 |
| ROCE % | 27% | 26% | 32% | 33% | 29% | 20% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - Of Schedule of Institutional Investors/Analyst meetings under the SEBI (LODR), Regulations, 2015, to be held on 19th November, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
5 Nov - Written transcript of Q2 and H1 FY25 earnings call.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29 Oct - Audio recording of earnings call uploaded.
-
Investor Presentation On Financial Results For The Quarter And Half Year Ended 30.09.2024
29 Oct - Investor presentation on Q2 and H1 FY25 financial results.
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Jul 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT REC
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Products
The company operates in various product segments, including insecticides, weedicides, fungicides, fumigants, rodenticides, plant growth nutrition products, bio-rationals, and plant growth regulators. It markets proprietary products from its Japanese parent, Sumitomo Chemical Co., in agrochemicals, animal nutrition, and environmental health.[1]
The products comprise conventional chemistry sourced from SCC, and biological products sourced from a USA-based subsidiary, Valent Biosciences LLC. [2]